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Abstract
Pure nucleotide precursor pools are a prerequisite for high-fidelity DNA replication and the suppression of mutagenesis and
carcinogenesis. ITPases are nucleoside triphosphate pyrophosphatases that clean the precursor pools of the non-canonical
triphosphates of inosine and xanthine. The precise role of the human ITPase, encoded by the ITPA gene, is not clearly
defined. ITPA is clinically important because a widespread polymorphism, 94C.A, leads to null ITPase activity in
erythrocytes and is associated with an adverse reaction to thiopurine drugs. We studied the cellular function of ITPA in HeLa
cells using the purine analog 6-N hydroxylaminopurine (HAP), whose triphosphate is also a substrate for ITPA. In this study,
we demonstrate that ITPA knockdown sensitizes HeLa cells to HAP-induced DNA breaks and apoptosis. The HAP-induced
DNA damage and cytotoxicity observed in ITPA knockdown cells are rescued by an overexpression of the yeast ITPase
encoded by the HAM1 gene. We further show that ITPA knockdown results in elevated mutagenesis in response to HAP
treatment. Our studies reveal the significance of ITPA in preventing base analog-induced apoptosis, DNA damage and
mutagenesis in human cells. This implies that individuals with defective ITPase are predisposed to genome damage by
impurities in nucleotide pools, which is drastically augmented by therapy with purine analogs. They are also at an elevated
risk for degenerative diseases and cancer.
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Introduction
The human genome is constantly attacked by exogenous or
endogenous DNA damaging agents. An accumulation of DNA
damage increases genome instability and mutagenesis, which
predisposes cells to neoplasia, as well as degenerative diseases
[1,2]. A prominent cause of endogenous DNA damage decreasing
the fidelity of DNA replication is contamination of the nucleotide
precursor pool with non-canonical nucleotides [3,4]. These
contaminants of the precursor pool include deoxy- and ribonu-
cleoside triphosphates of inosine (ITP/dITP), xanthine (XTP/
dXTP), 8-oxo-guanine (8-O-GTP/8-O-dGTP) and others, gener-
ated either as byproducts of cellular metabolism or by deamination
or oxidation of bases in natural nucleotides. Non-canonical
nucleotides contain analogs of the normal nitrogen bases (base
analogs), which gives some of them the unique property of
ambiguous base pairing during replication [5,6,7]. Incorporated
base analogs in DNA are repaired by the cellular repair systems,
which can result in the accumulation of DNA breaks [8,9]. If base
analogs in DNA escape the repair systems, their capacity for
ambiguous base pairing will lead to the accumulation of mutations
in the subsequent replication rounds [10,11]. Taking into
consideration the harmful effects of base analog incorporation, it
is not surprising that cells have developed elaborate enzymatic
systems that protect from base analog-induced DNA damage
[12,13]. These systems function at two levels. The first level
involves the interception of non-canonical nucleotides in the
precursor pool and their cleavage into di- or monophosphates.
The second level involves detection of improper bases after
incorporation and their direct removal from DNA. The former is
achieved by a class of enzymes called nucleoside triphosphatases
(NTPases) [3]. One such NTPase is evolutionary conserved
Inosine Triphosphate Pyrophosphatase (ITPA) [14].
ITPA is a human ITPase, whose function is to cleave inosine
triphosphate (ITP) and xanthine triphosphate (XTP) as well as
their deoxyribose forms into monophospates. This prevents the
incorporation of the nucleotide inosine (dITP), which contains the
base analog hypoxanthine, and dXTP into DNA [15]. ITPA is
expressed in many human tissues [15,16]. The importance of
ITPases is underscored by severe genome instability phenotypes
caused by deletion of the ITPA homologs in bacteria, yeast and
mice. A mutant of the bacterial ITPase, rdgB, is synthetically lethal
in combination with defects in recombination [8,9,17]. The
deletion of the budding yeast ITPase, HAM1, results in a drastic
elevation of mutagenesis induced by the model purine base analog
hydroxylaminopurine (HAP) [18]. The most severe phenotype for
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with ITPase knockout (genotype Itpa
2/2) are inviable [19]. The
mice that survive suffer from growth retardation and die before
weaning from cardiac failure. Fibroblasts obtained from the
ITPase knockout mice accumulated DNA single-strand breaks and
chromosomal abnormalities [20]. Therefore, in bacteria, yeast and
mice, the ITPase function plays an important role in maintaining
genomic integrity.
The precise cellular function of the human ITPase, ITPA, is not
clearly defined. There is a polymorphism in the ITPA gene in the
human population. Several alleles cause atypical ITPase activity
[21,22,23]. Clinically, the most relevant polymorphism is the
ITPAc.94C.A missense mutation that results in a substitution of
proline with threonine at position 32 (P32T). The allelic frequency
of this mutation ranges from 5 to19%, with the highest frequency
found in the Asian population [22]. Homozygotes for the P32T
mutation have no ITPase activity in erythrocytes, whereas
heterozygotes have approximately one-fourth ITPase activity.
Although ITPA deficiency in humans appears to be benign, the
administration of thiopurine therapy leads to adverse drug
reactions in these individuals [21,24,25].
To analyze the role of ITPA in human cells, we forced
nucleotide pool contamination by 6-hydroxyadenine (hydroxyla-
monipurine, abbreviated HAP). The dHAPTP is as good a
substrate for ITPA as ITP or XTP [26]. HAP is a potent mutagen
that can mispair with C or T and induce GC to AT and AT to GC
transitions [27,28]. Unlike most mutagens, HAP in non-recombi-
nogenic in yeast and its mutagenic action is independent of
translesion synthesis DNA polymerase, Pol f [29,30]. Nevertheless,
it is clastogenic in mammalian cells [31]. Most likely, HAP is
activated to deoxynucleoside triphosphate by a combination of
salvage and de novo purine biosynthesis pathways [26], but
definite genetic identification of the responsible enzymes has only
been obtained for the first step, conversion of the base to HAPMP
by phosphoribosyltransferases in bacteria and yeast (Stepchenkova
and Schaaper, personal communication and [32]). The dHAPTP
is readily incorporated into DNA by the replicative DNA
polymerases of bacteria and eukaryotes [27,33]and is repaired in
bacteria by the same systems as dITP and dXTP [9], thereby
enabling us to extrapolate the results obtained with HAP to
natural base analogs. Thus, the use of HAP provides us with a
good tool to investigate the protective effects of ITPA against
nucleotide pool contamination.
In this study, using the cervical carcinoma cell line HeLa and
HAP as a model, we demonstrate that ITPA knockdown sensitizes
human cells to base analog-induced DNA breakage, mutagenesis
and apoptosis. These phenotypes can be rescued by overexpress-
ing the yeast ITPase, HAM1, in the ITPA knockdown cells. Our
data suggest that ITPA plays a critical role in protecting human
cells against the cytotoxic, genotoxic and mutagenic effects of base
analogs. This implies that individuals with defective ITPase are at
an elevated risk for degenerative diseases and cancer.
Results
HAP incorporation into DNA of HeLa cells
It is known that hypoxanthine bases accumulate at a detectable
level in RNA and in DNA in Itpa knockout mice [19,20]. To find
whether HAP is present in DNA of treated HeLa cells, we studied
the appearance of endonuclease V-cleavable sites. HAP in DNA is
recognized by the product of the bacterial nfi gene, EndoV protein
[9]. The enzyme cuts the second bond 39 to the modified base and
leaves free 39 OH groups [34,35]. Such DNA will be a substrate
for nick translation and therefore, the incorporation of label by E.
coli DNA polymerases I would be proportional to the quantity of
such nicks [36]. We found that the number of EndoV cleavable
sites tremendously increases in DNA isolated from HeLa cells
grown in the presence of HAP (Fig. 1). This means that after
24 hours there is a substantial proportion of HAP in DNA, which
was not removed by DNA repair in human cells. We previously
detected DNA breaks, presumably being intermediate products of
repair of HAP, in the Comet assay after the same 24 hours [37].
While sensitive Comet assay detects some breaks, most HAP is still
present in DNA at this time. Massive removal of HAP achieved by
EndoV in vitro produces a strong signal in nick-translation assay.
HAP treatment triggers apoptosis in HeLa cells
Previously, it has been reported that HAP treatment results in
chromosomal fragmentation in human epidermoid cells [38]. This
effect appears to be cell line specific, because HAP did not induce
a chromosomal catastrophe in HCT116 cells [37]. This suggests
that HAP is potentially capable of causing devastating DNA
damage in human cells, but this is realized only under certain
conditions. We examined whether HAP treatment triggered
apoptosis in human cells. To do this, we determined the effects
of increasing doses of HAP on the viability of HeLa cells after
24 hours or 48 hours of treatment (Fig. 2A). After staining the cells
with Hoechst dye, we enumerated the number of apoptotic nuclei
by fluorescence microscopy. No effects of HAP treatment were
seen after 24 hours. After 48 hours of HAP treatment, we found
that 35% of the cells were apoptotic at a dose of 1.32 mM, while
42% of the cells underwent apoptosis at 1.98 mM. This increase is
significant (p,0.01) as compared to the 16% apoptosis observed at
these doses after 24 hours of treatment. The two-fold increase in
apoptotic cells observed after 48 hours of treatment suggests that
Figure 1. HAP treatment leads to the appearance of EndoV
sensitive sites in HeLa DNA. We extracted genomic DNA from HeLa
cells grown with or without HAP. Treatment of this DNA with bacterial
EndoV creates 39 nicks, which are substrates for nick-translation
(BioProbeH Nick translation kit with bio-16-dUTP (Enzo Life Sciences))
as described in Materials and Methods. A. Agarose gel electrophoresis
of nick-translated DNA from HeLa cells. 1- from untreated cells; 1a –
from untreated cells digested with DNase; 2 – from cells grown in
2.64 mM HAP; 3- from untreated cells, DNA incubated with Endo V; and
4 - from cells grown in 2.64 mM HAP, DNA incubated with Endo V. B.
Detection of newly synthesized biotinylated DNA separated by alkaline
agarose electrophoresis. 1- from untreated cells; 2 – from cells grown in
2.64 mM HAP; 3- from untreated cells, DNA incubated with Endo V; and
4 - from cells grown in 2.64 mM HAP, DNA incubated with Endo V.
doi:10.1371/journal.pone.0032313.g001
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for HAP to exert its cytotoxic effects.
By immunostaining of the whole cells as well as by immunoblot
we have shown that HAP treatment causes an induction of the
ITPA protein production in HCT116 cells [37]. We confirmed
that this was the case for HeLa cells as well. We observed that
ITPA protein levels were elevated after 24 hours as well as
48 hours after HAP treatment (Fig. 2B). The mechanism is
Figure 2. Effects of HAP treatment on apoptosis and ITPA levels in HeLa cells. (A) HAP treatment causes apoptosis in HeLa cells after
treatment for 24 or 48 hours. By two-way ANOVA, ptime=0.001 and pconcentration=0.0046. **p,0.01 by Bonferroni multiple comparison post test for
column analysis comparing means for 24 hours vs. 48 hours. (B) HAP treatment leads to the increase of ITPA protein levels in HeLa extracts following
treatment for both 24 hours and 48 hours. Western blots were performed as described in Materials and Methods. P- pure ITPA protein, C- untreated
control, DMSO – solvent only. (C) HAP treatment does not increase levels of ITPA transcripts. The analysis was performed as described in Materials and
Methods. HAP treatment was for 24 hours. Mr – 100 bp ladder.
doi:10.1371/journal.pone.0032313.g002
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demonstrated by RT-PCR (Fig. 2C). The induction of the ITPA
protein levels appeared to be more prominent after 48 hours. The
increase of ITPA protein production in response to HAP
treatment is consistent with the idea of a high demand for ITPA
when the precursor pool is contaminated with dHAPTP.
HAP-induced apoptosis occurs through the intrinsic
pathway
Apoptosis can occur by two pathways: either the extrinsic
pathway that involves death receptors or the intrinsic pathway that
occurs through the mitochondria. The intrinsic pathway can be
blocked by the overexpression of the anti-apoptotic protein Bcl-xL
[39]. To examine which pathway was involved in the case of HAP
treatment, we assayed for apoptosis following a 48-hour HAP
treatment of HeLa cells overexpressing Bcl-xL (henceforth referred
to as HeLa-xL) [40]. As evident from Fig. 3A, the HeLa-xL cells
were protected from HAP-induced apoptosis. We confirmed the
protection of HeLa-xL cells from HAP-induced apoptosis by
performing immunoblots for PARP cleavage, a hallmark of
apoptosis [41]. No PARP cleavage (Fig. 3B) was observed in
HeLa-xL cells, in a sharp contrast with HeLa cells.
HAP treatment causes an accumulation of DNA strand
breaks prior to the onset of apoptosis
Deletion of the E. coli ITPase, rdgB, results in the generation of
DNA breaks and chromosome fragmentation due to the excision
of hypoxanthine by Endo V [8,9,17]. We have previously shown
that HAP induces DNA breaks in human cells [37]. Most likely,
HAP in DNA is processed in a manner similar to the processing of
hypoxanthine by either the human homolog of Endo V or some
other yet to be identified enzymes. One possible candidate could
be the AAG glycosylase, which can excise hypoxanthine [42]. The
observation that HAP is capable of inducing apoptosis raised the
possibility that the breaks we observe reflect the onset of apoptotic
destruction of the nucleus. The HeLa-xL cells provided us with a
good tool for distinguishing between the two scenarios. As Bcl-xL
overexpression blocks apoptosis, we rationalized that DNA breaks
occurring during the repair of HAP incorporated into DNA would
not be affected by Bcl-xL overexpression and therefore could be
distinguished from DNA breaks caused by the process of apoptosis
itself. In the latter case, Bcl-xl overexpression would block the
appearance of DNA breaks as apoptosis itself is suppressed. We
studied the effect of increasing doses of HAP on the formation of
DNA breaks by alkaline comet assay after 24 hours of HAP
treatment in both cell lines. In prior experiments, this was a time
point where HAP treatment did not cause more than 16%
apoptosis. We observed that both cell lines accumulated similar
levels of DNA breaks (Fig. 3C). These data suggest that HAP
treatment does generate DNA breaks upstream to apoptosis.
ITPA knockdown cells are hypersensitive to HAP-induced
apoptosis
To investigate the role of ITPA in protecting against HAP-
induced cytotoxicity, we made stable knockdowns of ITPA by
transfecting HeLa with plasmids expressing shRNA that targeted
the ORF of ITPA. We obtained an efficient knockdown of ITPA
(Fig. S1). The ITPA knockdown cells were viable, indicating that it
is not an essential gene. Upon treatment with HAP for 24 hours,
30–50% of ITPA knockdown cells underwent apoptosis (p,0.001
for 0.66 mM, p,0.0001 for 1.32 mM and 1.98 mM) (Fig. 4). In
control HeLa cells, comparable levels of apoptosis were observed
only after 48 hours of treatment. No statistically significant
differences were observed for the untransfected and non-targeting
shRNA transfected controls. Thus, ITPA knockdown sensitizes
cells to HAP-induced apoptosis. Hydrogen peroxide treatment is
known to induce DNA breaks in HeLa cells and subsequently
cause apoptosis [43,44]. Therefore, we used this as a positive
control for our apoptosis assays to determine if HAP-induced
hypersensitivity to apoptosis was specific for ITPA knockdown. We
found that hydrogen peroxide treatment caused the same level of
apoptosis in all three cell lines. Taken together, our data suggest
that ITPA plays an important role in protecting HeLa cells against
HAP-induced apoptosis.
Suppression of HAP-induced apoptosis by
overexpression of ITPA or HAM1
In prior experiments we found that ITPA protein production
was induced in response to HAP treatment (Fig. 2B). This
suggested a putative role of ITPA in protecting against the harmful
effects of HAP. Moreover, we found that ITPA knockdown made
cells hypersensitive to HAP-induced apoptosis. To further establish
the protective role against HAP-induced apoptosis, we determined
whether overexpression of ITPA or its yeast ortholog, HAM1,
protected HeLa cells from HAP-induced apoptosis. We transfected
HeLa cells with two constructs where ITPase genes were under a
strong constitutive promoter. One expresses ITPA-GFP, encoding
for a fusion of ITPA with the GFP protein, another expresses
HAM1-GFP, encoding for a fusion of Ham1 with the GFP protein.
The production of both fusion proteins was confirmed by
immunoblot (Fig. S2A). We compared the apoptotic response at
a HAP dose of 1.98 mM for 48 hours. This dose of HAP caused
42% of the cells to undergo apoptosis (Fig. 3A). As compared to
the cells transfected with vector alone, ITPA overexpressing cells
were protected from HAP-induced apoptosis (Fig. 5A, p,0.01). A
similar level of protection was also observed in the case of HAM1
overexpression (p,0.05).
We have shown that the expression of wild-type ITPA as well
as HAM1 could efficiently rescue cells from apoptosis caused by
HAP treatment, suggesting that the yeast protein functions in the
foreign environment (Fig. 5A). Therefore, we rationalized that the
high expression of HAM1 should be able to complement the
defects caused by ITPA knockdown in those cells as well. We
anticipated that HAM1 would not be inhibited by shRNA
targeting ITPA. We confirmed the expression of the HAM1
construct and consequent protein production in the knockdown
cells by immunoblot (Fig. S2B). When we treated the transfec-
tants with 1.98 mM HAP for 48 hours, we found that
approximately 57% of cells transfected with the vector only
underwent apoptosis. However, cells transfected with the vector
expressing HAM1 were resistant, with only 13% undergoing
apoptosis (Fig. 4B) (p,0.0001). Thus, HAM1 complemented the
defect seen in the case of ITPA knockdown, proving that the
differences in the HAP sensitivity of normal and ITPA
knockdown cells are due to one gene, ITPA.
ITPA knockdown leads to elevated levels of HAP-induced
DNA breaks
We had previously demonstrated that human dermal fibroblasts
with endogenous ITPA-P32T (associated with null ITPase activity
in erythrocytes, as discussed in the Introduction) accumulated
more DNA breaks than the control fibroblast cell line with a wild-
type ITPA [37]. The availability of ITPA knockdown HeLa cells
transfected with control vector or vector expressing the yeast
HAM1gene allowed us to study the effects of HAP in nearly
isogenic cell lines. We assayed for levels of DNA breaks by alkaline
Human ITPA in Genome Stability and Apoptosis
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Bcl-xL. Both HeLa and HeLa-xL cell lines were treated with increasing doses of HAP for 48 hours and the percentage of apoptotic cells was
determined by Hoechst staining. By two-way ANOVA, pcell line,0.0001 and pconcentration=0.009. **p,0.01,***p,0.001 by Bonferroni multiple
comparison post test for column analysis comparing means for HeLa vs. HeLa-xL hours. (B) Confirmation of protection from HAP-induced apoptosis
by Bcl-xL overexpression by immunoblot for PARP cleavage. HAP induced dose-dependent cleavage of PARP in regular HeLa cells but not in HeLa
cells overexpressing Bcl-xL. PAPR cleavage product is marked as cl89. (C) HAP treatment results in similar levels of DNA breaks in HeLa and HeLa+Bcl-
xL cell lines (p.0.05).
doi:10.1371/journal.pone.0032313.g003
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any HAP-induced apoptosis, which would otherwise confound the
interpretation of the data since apoptosis itself causes DNA
fragmentation. We found that ITPA knockdown cells and ITPA
knockdown cells transfected with the empty vector accumulated
more DNA breaks than the knockdown cells overexpressing
HAM1 at low doses of HAP treatment (0.066–0.66 mM) (Fig. 6).
At higher doses of HAP, the comet tails in the knockdown cells
were too large to be precisely quantified. In the HAM1
overexpressing a knockdown cell comet tail at higher doses ranged
from 13 to 20%, which is slightly less that in the original HeLa,
Fig. 3C. No statistically significant difference in levels of DNA
breaks was observed in response to hydrogen peroxide treatment
in the three cell lines.
ITPA knockdown in HeLa cells elevates HAP-induced
mutagenesis
In addition to triggering apoptosis, we anticipated that
contamination of the nucleotide precursor pools with non-
canonical nucleotides could lead to elevated mutagenesis. HAP
has been shown to be mutagenic and carcinogenic in mammalian
cells [45,46]. It is known that the disruption of the HAM1 gene in
the budding yeast S. cerevisiae causes hypermutagenesis in response
to HAP treatment [18]. We therefore investigated whether this
Figure 4. ITPA protects against HAP-induced apoptosis. ITPA knockdown sensitizes cells to HAP-induced apoptosis. As compared to the
control and non-targeting shRNA transfected cells, ITPA knockdown cells undergo approximately 30–50% apoptosis upon HAP treatment for
24 hours. Hydrogen peroxide treatment (0.1 mM, four hours) was used as a positive control. The difference between control cells and cells with the
ITPA knockdown is highly significant (***p,0.001, ****p,0.0001). There was no difference between the control versus the non-targeting cell lines in
all HAP doses tested. No significant difference in hydrogen peroxide-induced apoptosis was observed for all three cell lines.
doi:10.1371/journal.pone.0032313.g004
Figure 5. ITPase overexpression suppresses HAP-induced cytotoxicity. (A) Effect of overexpression of the ITPA and the gene encoding yeast
ITPase, HAM1, on HAP-induced apoptosis in HeLa cells. Differences are significant (*p,0.05, **p,0.01). (B) Overexpression of the yeast HAM1 could
rescue ITPA knockdown cells from hypersensitivity to HAP-induced apoptosis (****p,0.0001, n.s., not significant).
doi:10.1371/journal.pone.0032313.g005
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We determined that HAP-induced mutant frequencies at the
HPRT locus (6-thioguanine resistance). The viability of HeLa cell
lines with or without ITPA knockdown was not affected by HAP
treatment. No statistically significant differences were observed
between the untransfected and shRNA-transfected cells in the
absence of HAP treatment. HAP was clearly mutagenic for HeLa
cells, increasing mutant frequency three-fold at 0.1 mM and 13-
fold at 1 mM (Suplementary Table 1). Next we compared HAP-
induced mutant frequencies for HeLa and ITPA knockdown cells
as described in Materials and Methods. We found that ITPA
knockdown cells were more sensitive to HAP-induced mutagenesis
at high doses as compared to the untransfected cells (p,0.01)
(Fig. 7). This suggests that ITPA plays a role in the protection from
HAP-induced mutations.
Discussion
An understanding of the role of ITPA in human cells is
important because several alleles representing polymorphism in
the ITPA gene are associated with the onset of thiopurine therapy-
related diseases. We probed the function of ITPA by determining
whether the enzyme protected HeLa cells against the harmful
effects of the model purine analog, HAP.
Previous reports have shown that HAP treatment results in
severe genotoxic stress to cells. HAP treatment causes chromo-
somal fragmentation and mutagenesis in human cells and in
Syrian hamster embryo cells [31,38]. We propose that HAP
incorporated into the DNA of human cells (Fig. 1) is being
repaired, intermediates of the repair cause breaks and these
persisting breaks cause apoptosis.
We found that HAP treatment induced apoptosis in HeLa cells.
The manifestation of apoptosis was prominent after 48 hours of
treatment (Fig. 2A). This is in contrast to genotoxicants directly
damaging DNA, like UV irradiation or hydrogen peroxide, which
induce apoptosis within 4–6 hours of treatment [40,43]. The
delayed response suggests that HAP needs to be activated to
dHAPTP and incorporated into DNA during replication in order
to exert its cytotoxic effects. At present, the exact pathway of HAP
activation in human cells is not known. We propose that it could
be similar to the hypothetical pathways proposed for bacteria and
yeast [26,32]. As HAP treatment is indicative of the effects of
nucleotide pool contamination, our data imply that elevated
Figure 6. ITPA protects against HAP-induced DNA breaks. Alkaline comet assay data reveals that as compared to the control and non-
targeting shRNA-expressing cell lines, ITPA knockdown cells accumulated elevated levels of DNA breaks after 24 hours of treatment with HAP. At
high doses of HAP, the sizes of the comet tails in the ITPA knockdown cells were too large to be quantified. The assay was performed at lower doses
of HAP treatment in order to obtain measurable comet tails. As compared to the cells with vector, the overexpression of HAM1 suppressed the
accumulation of HAP-induced DNA breaks in the ITPA knockdown cells. Statistical differences were measured by one-way ANOVA followed by Dunns
multiple comparisons for column analysis. By two-way ANOVA, p=0.008. Post-test analysis revealed differences (p,0.05) for knockdown versus
knockdown+HAM1 and knockdown+vector versus knockdown+HAM1. No difference in levels of DNA breaks was observed for hydrogen peroxide
treatment for all three cell lines.
doi:10.1371/journal.pone.0032313.g006
Figure 7. ITPA protects against HAP-induced mutagenesis. The
data represent the induced HPRT mutant frequency for the HAP-treated
control and ITPA knockdown cells. At a low dose (0.1 mM) of HAP
treatment for 24 hours the difference between cell lines was not
significant but at dose 1 mM ITPA knockdown cells were more sensitive
to HAP mutagenesis. (**p,0.01, n.s., not significant).
doi:10.1371/journal.pone.0032313.g007
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of base analogs into DNA causes apoptosis in human cells.
What is the mechanism underlying HAP cytotoxicity in human
cells? Using an analogy to experiments with bacteria, one
possibility is the generation of relatively long-lived single strand
DNA breaks as intermediates during the repair of HAP in DNA.
These breaks are converted to double strand breaks when the
replication fork encounters the discontinuity in the template
[9,47,48].
The incorporation of thiopurines into DNA causes DNA breaks
and subsequent apoptosis due to incomplete mismatch repair
[49,50]. An elevated level of the incorporation of 8-oxoG into
DNA triggers the accumulation of single-strand DNA breaks,
which results in cell death in mouse cells [51,52]. The situation
with 8-OG in mammalian cells is thus different from bacteria,
where no chromosomal DNA fragmentation occurs in the mutT
mutants [53]. It is possible that clastogenicity of base analogs
depends on the relative efficiency of the repair systems responsible
for their removal from DNA. We propose that HAP-induced
apoptosis is caused by persisting DNA breaks. We found that HAP
treatment triggered the accumulation of DNA breaks, which later
led to apoptosis in HeLa cells but not in HeLa-xL cells.
Presumably, these DNA breaks could be caused by the inefficient
excision of HAP from DNA by an uncharacterized glycosylase or
nuclease. Endo V has been shown to play a key role in this process
in E.coli lacking the ITPase gene, rdgB [9]. Orthologs of the nfi gene
encoding for endonuclease V have been characterized in mice and
found in the human genome [34,35,54]. The mouse enzyme was,
however, was 50 times less active than the bacterial Endo V. The
variants of human enzyme have been purified but no endonucle-
ase activity was detected (Waisertreiger, unpublished, R. Dalhus,
personal communication). The exact mechanism of HAP and
hypoxanthine repair in humans remains to be determined.
We found that knocking down ITPA by shRNA sensitized cells
to HAP-induced apoptosis (Fig. 4). The knockdown cells per se are
viable, thereby indicating that ITPA is not an essential gene in
human cells. Overexpression of the yeast HAM1 in the knockdown
cells rescued them from the cytotoxic effects of HAP. The
knockdown cells accumulated more DNA breaks, which were
suppressed in knockdown cells that overexpressed HAM1 (Figs. 5B
and 6). Thus, ITPA prevents the accumulation of HAP-induced
DNA damage. In passages of mouse embryonic fibroblasts, a
spontaneous increase in production of the NUDIX protein,
NUDT16, suppressed the genome instability phenotypes associat-
ed with Itpa deletion, thus suggesting a functional redundancy
between Itpa and NUDT16 [20]. Here, we did not observe any
redundancy for ITPA function. Although NUDIX proteins are
found in human cells, it is possible that they are activated under
special conditions. It is also possible that ITPA knockdown by itself
is insufficient to activate the expression of NUDIX genes in human
cells in a relatively limited number of passages. Another possibility
is that the functional redundancy between NUDIX genes and ITPA
is specific to mice. Collectively, we have shown that ITPA plays a
critical role in preventing HAP-induced apoptosis. This implies
that ITPA could play a role in protecting against the incorporation
of dITP/dXTP as well.
Thiopurines like azathioprine are commonly used immunosup-
pressive or anti-cancer drugs that exert their cytotoxic effects by
being converted into active nucleotides, which are then incorpo-
rated into DNA. ITPA is capable of destroying nucleoside
triphosphate of 6-MP [55]. A number of reports link chronic
immunosuppression/therapy with thiopurines like azathioprine
and the onset of therapy-induced cancer. One of the mechanisms
by which thiopurines bring about immunosuppression is by
causing the death of cytotoxic T lymphocytes, which is elicited
by the persistence of DNA breaks [50,56]. It is plausible that the
mechanism of cytotoxicity is similar for thiopurines and HAP.
Increased DNA damage can force cells to undergo either apoptosis
or senescence in order to prevent the passage of damaged DNA to
progeny cells. While apoptosis is critical for tissue homeostasis,
increased apoptosis is harmful because it can lead to organ
damage and degeneration. Elevated levels of DNA breaks and
apoptosis have been implicated as one of the causes of
degenerative diseases such as diabetes, arthritis, and cardiac
failure as well as neurodegenerative diseases like Alzheimer’s
disease, Huntington’s disease and Parkinson’s disease [57,58]. The
increased apoptosis observed in the ITPA knockdown cells in
response to HAP treatment is clinically relevant because it raises
the possibility that individuals with ITPase deficiency could be at
risk of developing therapy-induced organ damage and degener-
ation.
Therapy-induced cancer is a serious side effect of long-term
thiopurine-mediated immunosuppression [50,56]. In transplant
recipients, a decade long exposure to thiopurines like azathioprine
is associated with the onset of cancers such as leukemia and
squamous cell carcinomas. Moreover, there is a putative
association between P32T ITPA, prolonged azathioprine therapy
and the onset of carcinoma [59]. We have shown that ITPA
knockdown results in increased HAP-induced mutagenesis. This is
in line with our previous findings in yeast wherein HAP treatment
in yeast with a HAM1 mutation resulted in two orders of
magnitude higher mutagenesis as compared to their wild-type
counterparts [18,29]. In human cells, however, ITPA knockdown
did not result in such a dramatic phenotype as was observed with
yeast. The situation resembles the discrepancies in magnitude of
the effect of the absence of 8-oxoguanine triphosphatase in
bacteria (mutT is a very strong, up to 1000-fold, mutator [60]) and
mice (Mth
2/2 cells possess a very weak two-fold mutator
phenotype [61]). In spite of this relatively small effect on the
mutation rates, the deletion of Mth1caused an accumulation of 8-
oxoguanine in DNA and resulted in an increase in tumors in mice.
In our study, ITPA plays a more prominent role in prevention of
apoptosis that mutagenesis caused by HAP, suggesting that
different pathways lead to these events. It is also possible that
the yeast ham 1 mutant hypermutability maybe a very special case,
because yeast possess neither a molybdenum cofactor-dependent
pathway of HAP destruction [62,63], nor Endo V. Elevated levels
of DNA breaks and the increase in HAP-induced mutant
frequencies observed in the case of ITPA knockdown provide a
possible link between ITPA deficiency and a predisposition to
therapy-related and spontaneous cancer caused by intrinsic base
analogs.
We have demonstrated that the elevated nucleotide pool
contamination by nucleotides containing HAP, and by extrapo-
lation, endogenous hypoxanthine and xanthine, causes high levels
of apoptosis in human cells which, if unchecked, could lead to the
onset of degenerative diseases. We have uncovered the critical role
of ITPA in maintaining the stability of the genome and apoptosis in
human cells. Based on the data obtained in this study and concepts
generated with model systems, we propose the following model for
the role of ITPA in human cells (Fig. 8). In the presence of
functional ITPA, the accumulation of non-canonical nucleotides
like dITP, dXTP or dHAPTP is prevented due to the ITPase
activity. This precludes the accumulation of base analogs
hypoxanthine, xanthine or HAP into DNA and helps maintain
the genome stability. In the absence of functional ITPase, non-
canonical nucleotides accumulate in the precursor pool and base
analogs are incorporated into DNA by the replicative DNA
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of DNA single-strand breaks, which are converted to double-
strand breaks during replication. This triggers apoptosis and
increased levels of apoptosis contribute to the onset of
degenerative diseases. In the absence of repair, base analogs
persist in DNA, causing errors in replication. This leads to the
accumulation of mutations, which predisposes individuals to
cancer development. Overall, the findings from this study suggest
that ITPA is an important factor in the maintenance of genome
stability and protection from the onset of therapy-induced
degenerative diseases and cancer.
It is also worth mentioning that, in some cases, the defect of
ITPA could be a benefit in special situations, because the
condition prevents hemolytic anemia in hepatitis C patients
treated by ribavirin [64]. This might partially explain why ITPA-
P32T allele is retained in population and demands further studies
of the role of ITPA and its variants in humans.
Materials and Methods
Cells and cell culture
HeLa cervical carcinoma cell line and its derivative overex-
pressing Bcl-xL (HeLa-xL) were described previously [40]. Both
cell lines were cultivated in DMEM (Invitrogen, U.S.A.)
containing 10% fetal bovine serum (FBS, Gibco) at 37uCi na
5% CO2 atmosphere.
Chemicals
The base analog 6N-hydroxylaminopurine (HAP) was obtained
from MP Biologicals Inc. U.S.A. Stocks of HAP were prepared in
DMSO and heated slightly to facilitate dissolution of HAP
powder. Hydrogen peroxide (H1009) was obtained from Sigma
Co (St. Louis, MO). Doses of HAP used in the experiments ranged
from 0.066 mM to 1.98 mM, which corresponded to concentra-
tions of 10 mg/mL to 300 mg/mL.
Transfection of human cells and generation of stable cell
lines
Transfection experiments were carried out using Lipofectamine
LTX reagent (Invitrogen, U.S.A.) according to the manufacturer’s
instructions. Plasmids for the expression of shRNA against ITPA
(Cat # KH0744P) were purchased from SABiosciences (MD). The
shRNA encoded by these plasmids target the ORF of ITPA. HeLa
cells were transfected by the four plasmids individually and
assayed for knockdown efficiency by immunoblot and HAP
cytotoxicity by Hoechst staining. As per the instructions provided
by the manufacturer, the two plasmids with the highest
knockdown efficiency were selected for creating cell lines with
stable ITPA knockdown. In this case, 1 mg each of plasmids 1 and
2 were used for co-transfection and stable maintenance of plasmids
was achieved by selection for puromycin resistance. Stable
transfectants were cultivated in DMEM+10% FBS+3 mg/mL
puromycin for at least one week before proceeding with further
experimentation. ITPA stable knockdown typically lasted for about
three weeks.
Plasmid construction
DNA fragments with ITPA and HAM1 were PCR-amplified
from previously constructed bacterial expression plasmids
Figure 8. Model for the protective role of ITPA against HAP-induced genotoxicity and mutagenesis. In the presence of functional ITPA,
the accumulation of non-canonical nucleotides like dHAPTP is abrogated by the ITPase, thereby preventing their incorporation into DNA. In the
absence of functional ITPase, dHAPTP accumulates in the precursor pool and is incorporated into DNA by the replicative DNA polymerases. Grey
circles represent HAP accumulation in DNA. Slow excision of base analogs by an unknown nuclease/glycosylase results in the accumulation of single-
strand DNA breaks, which triggers apoptosis. Increased levels of apoptosis contribute to the onset of degenerative diseases. In the absence of repair,
HAP persists in DNA causing incorrect pairing with T or C, thus leading to the accumulation of mutations, which predisposes individuals to the
development of cancer.
doi:10.1371/journal.pone.0032313.g008
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of the mammalian expression vector pEGFP-C1 in frame with
GFP.
Antibodies
Antibody against PARP (#9542) was purchased from Cell
Signaling. Antibody against b-Actin (A5441) was purchased from
Sigma Co (St. Louis, MO). Antibody against GFP (SC9996) was
purchased from Santa Cruz Biotechnology Inc. The polyclonal
antibody against ITPA was developed in–house [67].
Immunoblotting
HeLa cells were harvested by scraping with plastic scrapers and
pelleted at 1000 g at 4uC. The cell pellets were washed twice to
remove traces of medium. Lysates were prepared by resuspending
the harvested cell pellets in NP-40 lysis buffer containing 0.1 mM
PMSF, 16 HALT protease inhibitor cocktail (Fisher Scientific)
and 1 mM sodium orthovanadate. Protein concentrations in the
lysates were determined by a Bradford assay (Biorad). Separation
of proteins was done by SDS PAGE. The amount of lysate
corresponding to 50 mg of protein was boiled in Laemmli’s buffer
containing 0.1 M DTT and then loaded onto a 4–20% Tris-
Glycine gel (Invitrogen, U.S.A.). Resolved proteins were trans-
ferred onto a PVDF (Millipore) membrane and blocked in 5%
non-fat dry milk/16 PBST for 20 min. Thereafter, membranes
were incubated with the appropriate dilution of the primary
antibody with shaking overnight at 4uC. Membranes were washed
three times in 16 PBST for 10 min each and incubated with
appropriately diluted HRP-linked secondary antibody (Fisher
Scientific) for one hour at room temperature. The membrane
was washed three times in 16PBST for 15 min each, and signals
were detected by Immobilion Western chemiluminescent HRP
substrate (ECL, Millipore), according to the manufacturer’s
instructions.
RT-PCR
Total RNA was extracted using RNeasy Kit (Qiagen). The
cDNA was synthesized from 2 mg of RNA using the Superscript
III first strand cDNA synthesis kit (Invitrogen), according to the
manufacturer’s instructions. The part of the ITPA transcript was
amplified using the primers 59-TCATTGGTGGGGAAGAA-
GATC-39 and 59AAGCTGCCAAACTGCCAAA-39. PCR am-
plification using these primers gives 550 bp of product. The
primers 59-TCCACCACCCTGTTGCTGTA-39 and 59-ACCA-
CAGTCCATGCCATCAC-39 were used for amplification of the
part of the housekeeping gene GAPDH transcript to give a product
of 108 bp.
Quantification of the levels of apoptosis
Apoptosis was quantified according to nuclear morphology by
using Hoechst 33342 at 1 mg/mL (Molecular Probes). Three
different viewing areas were randomly chosen for each experi-
ment. Pictures containing approximately 300 cells were taken for
each Hoechst stained viewing area. The percentage of cells
undergoing nuclear condensation was calculated for each viewing
area. At least three independent experiments were quantified for
each data point.
Alkaline comet assay for assessing accumulation of DNA
breaks
Comet assay with HAP was described previously. All of the
required chemicals were purchased from Trevigen, Inc. (U.S.A.)
[37].
Determination of the frequency of HAP-induced HPRT
mutants
Parent HeLa cells and ITPA knockdown cells were plated at a
density of 10 million cells per 10 cm dish. Cells were allowed to
attach overnight, following which the growth medium was
replaced with fresh medium or by medium with the appropriate
dose of HAP. Cells were incubated for 24 hours and then the
treatment medium was replaced with normal growth medium for
24 hours to allow for phenotypic expression of 6-TG resistant
mutants. Cells were then trypsinized and 10
7 cells were plated
onto twenty 10 cm dishes containing growth medium supple-
mented with 6 mg/mL 6-thioguanine (Sigma, St. Louis, MO) at a
density of 5610
5 cells per plate. For plating efficiency, cells were
plated in three plates with normal growth medium at a density of
5610
2 per plate. After two weeks, cells were fixed with 70%
ethanol and stained with 5% Giemsa solution in PBS. Colonies
were counted macroscopically for plating efficiency. For 6-TG
resistance, colonies were counted using an inverted light
microscope at 106magnification. Aggregates of 50 cells or more
were scored as a colony. Mutant frequency was calculated using
the formula of Glaab and Tyndall (49):
MF~number of 6TG{resistant colonies=
10000000   Plating efficiency=1500 ðÞ ðÞ :
This experiment was repeated three times with three consecutive
passages of cells. In every experiment we determined the induced
mutant frequency, where the background mutant frequency of
untreated cells was subtracted from the frequency of mutants in
the HAP treated cultures. Spontaneous mutant frequencies in
these experiments ranged from 100 to 500610
27, which is
consistent with the published data for HeLa and it derivatives [68].
Statistical analyses
Each experiment was repeated independently at least twice. All
data are expressed as mean +/2SEM of several experiments.
Statistical analysis was performed using Graphpad PRISM
software (PRISM, CA). Unless otherwise indicated, statistically
significant differences between means were estimated using two-
way ANOVA to compare concentrations and cell lines. The
Bonferroni multiple comparison post-test was used to analyze
differences between groups. Values were considered statistically
different if the probability of the difference by random fluctuation
was less than 0.05.
Supporting Information
Figure S1 ITPA knockdown in HeLa cells. HeLa cells
stably expressing shRNA against ITPA were immunoblotted for
the level of ITPA protein. Cells expressing shRNA against ITPA
showed an almost complete inhibition of ITPA protein produc-
tion.
(TIF)
Figure S2 ITPases overproduction in HeLa cells. Immu-
noblot for eGFP in cells transfected with constructs expressing
either ITPA or HAM1 as GFP fusion proteins. Cells transfected
with vector showed a lower molecular weight band of 27 kDa
corresponding to the molecular weight of eGFP. Cells transfected
with the ITPA-GFP and HAM1-GFP showed higher molecular
weight bands of approximately 50 kDa, corresponding to the
weights of the two GFP fusions with ITPases. We show the
immunoblot for eGFP in ITPA knockdown cells. HeLa cells with
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Ham1 as a GFP fusion protein.
(TIF)
Table S1 Frequencies of spontaneous and HAP-induced
HRPT mutants in HeLa cells.
(DOC)
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